Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts

References

• Albert, J. M., et al., 2007. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clinical Cancer Research, 13 (10), 3033–3042.
   PubMed Web of Science ®Google Scholar
• Albuquerque, K., et al., 2016. Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer. International Journal of Gynecological Cancer, 26 (4), 655–660.
   PubMed Web of Science ®Google Scholar
• Ashworth, A. and Lord, C. J., 2018. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nature Reviews. Clinical Oncology, 15 (9), 564–576.
   PubMed Web of Science ®Google Scholar
• Begg, A.C., 1990. Cisplatin and radiation: interaction probabilities and therapeutic possibilities. International Journal of Radiation Oncology, Biology, Physics, 19 (5), 1183–1189.
   PubMed Web of Science ®Google Scholar
• Bhatla, N., et al., 2018. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics, 143 (S2), 22–36.
   PubMedGoogle Scholar
• Bizzarri, N., et al., 2021. Peritoneal HPV-DNA test in cervical cancer (PIONEER study): a proof of concept. International Journal of Cancer, 148 (5), 1197–1207.
   PubMed Web of Science ®Google Scholar
• Bridges, K.A., et al., 2014. Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget, 5 (13), 5076–5086.
   PubMed Web of Science ®Google Scholar
• Brock, W.A., et al., 2004. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Letters, 205 (2), 155–160.
   PubMed Web of Science ®Google Scholar
• Calabrese, C.R., et al., 2004. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute, 96 (1), 56–67.
   PubMedGoogle Scholar
• Chundury, A., et al., 2016. Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. Gynecologic Oncology, 141 (1), 134–139.
   PubMed Web of Science ®Google Scholar
• Curtin, N. and Szabo, C., 2013. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Molecular Aspects of Medicine, 34 (6), 1217–1256.
   PubMed Web of Science ®Google Scholar
• Farhood, B., et al., 2019. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clinical & Translational Oncology, 21 (3), 268–279.
   PubMed Web of Science ®Google Scholar
• Gong, L., et al., 2021. Application of radiosensitizers in cancer radiotherapy. International Journal of Nanomedicine, 16, 1083–1102.
   PubMed Web of Science ®Google Scholar
• Hegan, D.C., et al., 2010. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings of the National Academy of Sciences of the United States of America, 107 (5), 2201–2206.
   PubMed Web of Science ®Google Scholar
• Jones, P., et al., 2009. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. Journal of Medicinal Chemistry, 52 (22), 7170–7185.
   PubMed Web of Science ®Google Scholar
• Konecny, G.E. and Kristeleit, R.S., 2016. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. British Journal of Cancer, 115 (10), 1157–1173.
   PubMed Web of Science ®Google Scholar
• Lazzari, R., et al., 2018. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. International Journal of Radiation Oncology, Biology, Physics, 101 (3), 650–660.
   PubMed Web of Science ®Google Scholar
• Lesueur, P., et al., 2017. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget, 8 (40), 69105–69124.
   PubMedGoogle Scholar
• Li, L. T., et al., 2015. Ki67 is a promising molecular target in the diagnosis of cancer. Molecular Medicine Reports, 11 (3), 1566–1572.
   PubMed Web of Science ®Google Scholar
• Lord, C.J. and Ashworth, A., 2017. PARP inhibitors: synthetic lethality in the clinic. Science, 355 (6330), 1152–1158.
   PubMed Web of Science ®Google Scholar
• Mao, Y., et al., 2018. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. Cancer Medicine, 7 (4), 1285–1296.
   PubMed Web of Science ®Google Scholar
• Mesko, S., et al., 2017. Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies. International Journal of Gynecological Cancer, 27 (2), 403–408.
   PubMed Web of Science ®Google Scholar
• Murai, J., et al., 2012. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Research, 72 (21), 5588–5599.
   PubMed Web of Science ®Google Scholar
• Pearcey, R., et al., 2002. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. Journal of Clinical Oncology, 20 (4), 966–972.
   PubMed Web of Science ®Google Scholar
• Pollom, E. L., et al., 2017. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Medicine, 6 (1), 129–141.
   PubMed Web of Science ®Google Scholar
• Pommier, Y., O'Connor, M.J. and de Bono, J., 2016. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Science Translational Medicine, 8 (362), 362ps17.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri, A. and Nussenzweig, A., 2017. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nature Reviews. Molecular Cell Biology, 18 (10), 610–621.
   PubMed Web of Science ®Google Scholar
• Rose, P.G., et al., 1999. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine, 340 (15), 1144–1153.
   PubMed Web of Science ®Google Scholar
• Sandhu, S.K., et al., 2010. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. Journal of Clinical Oncology, 28 (15 Suppl.), 3001.
   Web of Science ®Google Scholar
• Scott, C.L., Swisher, E.M., and Kaufmann, S.H., 2015. Poly(ADP-ribose) polymerase inhibitors: recent advances and future development. Journal of Clinical Oncology, 33 (12), 1397–1406.
   PubMed Web of Science ®Google Scholar
• Senra, J.M., et al., 2011. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Molecular Cancer Therapeutics, 10 (10), 1949–1958.
   PubMed Web of Science ®Google Scholar
• Singh, D., et al., 2023. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet Global Health, 11 (2), e197–e206.
   PubMed Web of Science ®Google Scholar
• Singh, M., et al., 2022. Secular trends in incidence and mortality of cervical cancer in India and its states. BMC Cancer, 22, 1–12.
   PubMed Web of Science ®Google Scholar
• Tuli, R., et al., 2014. Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly(ADP-ribose) polymerase inhibition with ABT-888. Translational Oncology, 7 (3), 439–445.
   PubMed Web of Science ®Google Scholar
• Valenti, G., et al., 2017. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates in Surgery, 69 (4), 441–449.
   PubMed Web of Science ®Google Scholar
• Vordermark, D., 2016. Radiotherapy of cervical cancer. Oncology Research and Treatment, 39 (9), 516–520.
   PubMed Web of Science ®Google Scholar
• Wang, L., et al., 2012. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Investigational New Drugs, 30 (6), 2113–2120.
   PubMed Web of Science ®Google Scholar
• WHO, 2021. Cervical cancer. Available from: https://www.who.int/westernpacific/health-topics/cervical-cancer [Accessed 20 May].
   Google Scholar
• Yang, M., et al., 2022. Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: an international comparative study based on the Global Burden of Disease. BMJ Open, 12 (7), e055470.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2019. Effect of radiotherapy on the survival of cervical cancer patients: an analysis based on SEER database. Medicine, 98 (30), e16421.
   PubMed Web of Science ®Google Scholar